Audio long read: The ‘breakthrough’ obesity drugs that have stunned researchers
Nature Podcast
00:00
Tezepitide Is a GLP1 Imitator
Eli Lilly plans to apply for the drug to be approved, pending results from a second phase 3 trial wrapping up in April 2023. The levels of weight loss following Tezepitide treatment approach those typically achievable only through bariatric surgery. This procedure reduces body weight by 30% or more after 6 months, and the weight loss continues for the next year or two.
Transcript
Play full episode
